Alkermes plc ALKS.US 總覽分析
)ALKS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
ALKS 近期報酬表現
3.78%
Alkermes plc
4.57%
同產業平均
3.26%
S&P500
與 ALKS 同產業的標的表現
- PLRZ Polyrizon ltd價值 -趨勢 2 分波段 2 分籌碼 -股利 1 分查看更多
ALKS 公司資訊
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.